BDRX
Biodexa Pharmaceuticals Plc

12,539
Mkt Cap
$898,300.00
Volume
3.81M
52W High
$92.00
52W Low
$1.40
PE Ratio
-0.02
BDRX Fundamentals
Price
$1.45
Prev Close
$1.63
Open
$1.59
50D MA
$3.38
Beta
1.22
Avg. Volume
324,604.70
EPS (Annual)
-$148.23
P/B
3.41
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
News Placeholder
Biodexa Promotes Fiona Sharp To CFO As Stephen Stamp Cedes Role To Become Only CEO
(RTTNews) - Biodexa Pharmaceuticals Plc (BDRX), a clinical stage biopharmaceutical company, Monday announced that it has promoted Fiona Sharp to Chief Financial Officer and Company Secretary...
Nasdaq News: Markets·1mo ago
News Placeholder
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock?
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·5mo ago
News Placeholder
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Zacks·9mo ago
News Placeholder
Biodexa Stock Surges On FDA's Fast-Track Tag For Treatment Of Cancer-Causing Condition: Retail Confidence Peaks
The drug, a proprietary encapsulated form of rapamycin, is being developed for familial adenomatous polyposis (FAP), a condition that, if left untreated, universally leads to colorectal cancer.
Stocktwits·1y ago
<
...
1
>

Latest BDRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.